Evidence map›Paper›PMID 30830040›Full record

ArticleTransplantation2019

Antibody-suppressor CD8+ T Cells Require CXCR5.

Jason M Zimmerer, Bryce A Ringwald, Steven M Elzein, Christina L Avila, Robert T Warren, Mahmoud Abdel-Rasoul, Ginny L Bumgardner

Open access · greenAbstract read
In one paragraph

Article in Transplantation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Antibody-suppressor CXCR5American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2022
    Article
  6. The diagnostic role of PD-1Journal of clinical laboratory analysis · 2022
    Article
  7. CXCR5Frontiers in medicine · 2022
    Review
  8. Review
  9. Harnessing CD8Cells · 2021
    Review
  10. CXCR5Journal of immunology (Baltimore, Md. : 1950) · 2021
    Review
  11. Article
  12. Review
  13. CD8Frontiers in immunology · 2020
    Review
  14. Future prospects for CD8Immunological reviews · 2019
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jason M ZimmererDepartment of Surgery, Comprehensive Transplant Center, The Ohio State University, Columbus, OH.
Bryce A RingwaldMedical Student Research Program, The Ohio State University College of Medicine, Columbus, OH.
Steven M ElzeinMedical Student Research Program, The Ohio State University College of Medicine, Columbus, OH.
Christina L AvilaDepartment of Surgery, Comprehensive Transplant Center, The Ohio State University, Columbus, OH.
Robert T WarrenDepartment of Surgery, Comprehensive Transplant Center, The Ohio State University, Columbus, OH.
Mahmoud Abdel-RasoulCenter for Biostatistics, The Ohio State University, Columbus, OH.
Ginny L BumgardnerDepartment of Surgery, Comprehensive Transplant Center, The Ohio State University, Columbus, OH.
The Ohio State University · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3M
Novel Mechanisms Regulating Posttransplant Humoral AlloimmunityR01AI083456 · NIAID · OHIO STATE UNIVERSITY · PI BUMGARDNER, GINNY L · 2011 to 2014
$1.5M
NCI NIH HHS P30 CA016058NIAID NIH HHS R01 AI083456
6 · The paper itself

Abstract

backgroundWe previously reported the novel activity of alloprimed CD8 T cells that suppress posttransplant alloantibody production. The purpose of the study is to investigate the expression and role of CXCR5 on antibody-suppressor CD8 T-cell function.

methodsC57BL/6 mice were transplanted with FVB/N hepatocytes. Alloprimed CD8 T cells were retrieved on day 7 from hepatocyte transplant recipients. Unsorted or flow-sorted (CXCR5CXCR3 and CXCR3CXCR5) alloprimed CD8 T-cell subsets were analyzed for in vitro cytotoxicity and capacity to inhibit in vivo alloantibody production following adoptive transfer into C57BL/6 or high alloantibody-producing CD8 knock out (KO) hepatocyte transplant recipients. Alloantibody titer was assessed in CD8 KO mice reconstituted with naive CD8 T cells retrieved from C57BL/6, CXCR5 KO, or CXCR3 KO mice. Antibody suppression by ovalbumin (OVA)-primed monoclonal OVA-specific t-cell receptor transgenic CD8+ T cells (OT-I) CXCR5 or CXCR3 CD8 T-cell subsets was also investigated.

resultsAlloprimed CXCR5CXCR3CD8 T cells mediated in vitro cytotoxicity of alloprimed "self" B cells, while CXCR3CXCR5CD8 T cells did not. Only flow-sorted alloprimed CXCR5CXCR3CD8 T cells (not flow-sorted alloprimed CXCR3CXCR5CD8 T cells) suppressed alloantibody production and enhanced graft survival when transferred into transplant recipients. Unlike CD8 T cells from wild-type or CXCR3 KO mice, CD8 T cells from CXCR5 KO mice do not develop alloantibody-suppressor function. Similarly, only flow-sorted CXCR5CXCR3 (and not CXCR3CXCR5) OVA-primed OT-I CD8 T cells mediated in vivo suppression of anti-OVA antibody production.

conclusionsThese data support the conclusion that expression of CXCR5 by antigen-primed CD8 T cells is critical for the function of antibody-suppressor CD8 T cells.

Indexed as

Antibody-Dependent Cell CytotoxicityLiver TransplantationAnimalsB-LymphocytesCD8 AntigensCD8-Positive T-LymphocytesCells, CulturedCoculture TechniquesFemaleGraft RejectionGraft SurvivalHepatocytesMaleMice, Inbred C57BLMice, KnockoutReceptors, CXCR3CD8 AntigensCxcr3 protein, mouseCXCR5 protein, mouseReceptors, CXCR3Receptors, CXCR5

Identifiers

PMID30830040
PMCPMC6713619
OpenAlexW2921028124

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.